Try it as your roleGet started

CVX vaccine codes

CVX is the CDC’s code list for vaccines given. These are the 139 codes for vaccines in use today, in the US and elsewhere, with the national schedules that name each one.

100 codes

Active in the United States

CVXVaccineOn these schedules
143Adenovirus types 4 and 7Adenovirus, type 4 and type 7, live, oralThis vaccine is administered as 2 tablets.—
318Anthrax, post-exposure prophylaxisAnthrax vaccine, adsorbed, adjuvanted, post-exposure prophylaxisNational stockpile vaccine (Cyfendus)—
24Anthrax, pre-exposure prophylaxis, post-exposure prophylaxisAnthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis—
19BCGBacillus Calmette-Guerin vaccineIndia UIP, India IAP
317Chikungunya live attenuated vaccine, 0.5 mL, PFChikungunya, live attenuated vaccine, 0.5 mL, preservative freeChikungunya Vaccine—
329Chikungunya, VLP, recombinant, 0.8 mL, PFChikungunya, virus-like particle (VLP), recombinant vaccine, 0.8 mL, preservative free—
174cholera, live attenuated—
334COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 10 mcg/0.2 mL doseModerna monovalent new formulation mNEXSPIKE, starting Fall 2025, ages 12 yrs and older, BLA—
311COVID-19, mRNA, LNP-S, PF, 25 mcg/0.25 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 25 mcg/0.25 mL doseModerna Fall Seasonal 6 months through 11 years of age—
312COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL doseModerna Fall Seasonal 12 years and older—
310COVID-19, mRNA, LNP-S, PF, tris-sucrose, 10 mcg/0.3 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 10 mcg/0.3 mL dosePfizer Fall Seasonal 5 years through 11 years of age—
309COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mLSARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, tris-sucrose, 30 mcg/0.3 mL dosePfizer Fall Seasonal 12 years and older—
313COVID-19, subunit, rS-nanoparticle, adjuvanted, PF, 5 mcg/0.5 mLSARS-COV-2 (COVID-19) vaccine, subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 5 mcg/0.5 mL doseNovavax Fall Seasonal 12 years and older—
56dengue fever tetravalentdengue fever vaccine, tetravalentApplies to tetravalent product (e.g. DENGVAXIA)—
20DTaPdiphtheria, tetanus toxoids and acellular pertussis vaccineAustralia NIP
110DTaP-Hep B-IPVDTaP-hepatitis B and poliovirus vaccine—
120DTaP-Hib-IPVdiphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)Canada CIG
130DTaP-IPVDiphtheria, tetanus toxoids and acellular pertussis vaccine, and poliovirus vaccine, inactivatedCanada CIG, Australia NIP
106DTaP, 5 pertussis antigensdiphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigensAustralia NIP
146DTaP,IPV,Hib,HepBDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Protein Conjugate), and Hepatitis B (Recombinant) Vaccine.This vaccine is different from CVX 132. Code may be used to document non-US vaccines (e.g. Hexamin) of the same component formulationNHS routine, Australia NIP
204Ebola Zaire vaccine, live, recombinant, 1mL doseFDA Approved ERVEBO Vaccine.—
104Hep A-Hep Bhepatitis A and hepatitis B vaccine—
52Hep A, adulthepatitis A vaccine, adult dosage—
83Hep A, ped/adol, 2 dosehepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule—
8Hep B, adolescent or pediatrichepatitis B vaccine, pediatric or pediatric/adolescent dosageThis code applies to any standard pediatric formulation of Hepatitis B vaccine. It should not be used for the 2-dose hepatitis B schedule for adolescents (11-15 year olds). Use code 43 for that vaccine.India UIP, India IAP, Australia NIP
43Hep B, adulthepatitis B vaccine, adult dosageThis code applies to any standard adult dose and schedule. Also use CVX 43 for the FDA approved Recombivax HB 2-dose hepatitis B schedule for adolescents (11-15 year olds) using the adult formulation.—
44Hep B, high-dosage, dialysis or ICHepatitis B vaccine (Hep B), high-dosage, dialysis or immunocompromised patientThis code is used record patient high dosage vaccine administration for dialysis or immunocompromised patients. For NDCs that are used for both regular vaccine and dialysis/IC high-dosage schedules (e.g. Engerix-B), are mapped to both CVX 43 and CVX 44. CVX code 44 should be utilized to record dialysis/IC dosing.—
189HepB-CpGHepatitis B vaccine (recombinant), CpG adjuvanted—
49Hib (PRP-OMP)Haemophilus influenzae type b vaccine, PRP-OMP conjugate—
48Hib (PRP-T)Haemophilus influenzae type b vaccine, PRP-T conjugateAustralia NIP
62HPV, quadrivalenthuman papilloma virus vaccine, quadrivalentIndia UIP
165HPV9Human Papillomavirus 9-valent vaccineNHS routine, Canada CIG, Australia NIP
160Influenza A monovalent (H5N1), ADJUVANTED-2013Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013Approved by FDA 2013, adjuvant is mixed at point of administration.—
321Influenza-avian, H5N8, monovalent, PFInfluenza-avian, H5N8, viral-vector, monovalent, injectable, preservative freeNovel Bird Flu H5N8 Vaccine 2024—
322Influenza-avian, H5N8, monovalent, preservativeInfluenza-avian, H5N8, viral-vector, monovalent, injectable, contains preservativeNovel Bird Flu H5N8 Vaccine 2024—
205Influenza, adjuvanted, quadrivalent, PFInfluenza, adjuvanted, inactivated, quadrivalent, injectable, preservative freeQuadrivalent code starting 2020/2021 season—
168Influenza, adjuvanted, trivalent, PFInfluenza, adjuvanted, inactivated, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season—
197Influenza, high-dose, quadrivalent, PFInfluenza, high-dose, split virus, quadrivalent, injectable, preservative freeQuadrivalent code starting season 2020/2021—
135Influenza, high-dose, trivalent, PFInfluenza, high-dose, split virus, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season—
161Influenza, injectable,quadrivalent, preservative free, pediatric—
149Influenza, live, quadrivalent, intranasalQuadrivalent code starting 2013/2014 season—
111Influenza, live, trivalent, intranasal, PFInfluenza, live, trivalent, intranasal, preservative freeHCP administered, trivalent code reactivated for 2024/2025 season—
333Influenza, live, trivalent, intranasal, self/caregiver admin, PFInfluenza, live, trivalent, intranasal, self or caregiver administered, preservative freeSelf or caregiver administered, new starting 2025/2026 season—
171Influenza, MDCK, quadrivalent, PFInfluenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, preservative freeQuadrivalent code starting 2016/2017 season—
186Influenza, MDCK, quadrivalent, preservativeInfluenza, Madin Darby Canine Kidney, subunit, quadrivalent, injectable, contains preservativeQuadrivalent code starting 2017/2018 season—
153Influenza, MDCK, trivalent, PFInfluenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season—
320Influenza, MDCK, trivalent, preservativeInfluenza, Madin Darby Canine Kidney, subunit, trivalent, injectable, contains preservativeTrivalent code starting 2024/2025 season—
338Influenza, mRNA, trivalent, PFInfluenza, mRNA lipid nanoparticle, trivalent, injectable, 0.38 mL dose, preservative-freemRNA influenza vaccine FDA approved 08/05/2026 starting with Fall 2026/2027 season—
185Influenza, recombinant, quadrivalent, PFInfluenza, recombinant, quadrivalent, injectable, preservative freeQuadrivalent code starting 2017/2018 season—
155Influenza, recombinant, trivalent, PFInfluenza, recombinant, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season—
231influenza, Southern Hemisphere, high-dose, quadrivalentinfluenza, seasonal, Southern Hemisphere, high-dose, quadrivalent, 0.7mL dose, preservative freeTarget population 65 and older, starting Southern Hemisphere season 2023—
337Influenza, Southern Hemisphere, high-dose, trivalent, PFInfluenza, Southern Hemisphere, high-dose, split virus, trivalent, 0.5 mL, injectable, preservative freeCode created starting 2026 Southern Hemisphere season—
200influenza, Southern Hemisphere, pediatric, preservative freeinfluenza, seasonal, Southern Hemisphere, quadrivalent, pediatric 0.25mL dose, preservative freePediatric dose for ages 6-35 months—
201Influenza, Southern Hemisphere, quadrivalent, PFInfluenza, seasonal, Southern Hemisphere, quadrivalent, 0.5 mL dose, preservative freeRepresents single dose vial—
202influenza, Southern Hemisphere, quadrivalent, with preservativeinfluenza, seasonal, Southern Hemisphere, quadrivalent, 0.5mL dose, with preservativeRepresents multi-dose vial—
331Influenza, Southern Hemisphere, trivalent, PFInfluenza, seasonal, Southern Hemisphere, trivalent, 0.5 mL dose, preservative freeRepresents single dose vial—
150Influenza, split virus, quadrivalent, PFInfluenza, split virus, quadrivalent, injectable, preservative freeQuadrivalent code starting 2013/2014 season—
158Influenza, split virus, quadrivalent, preservativeInfluenza, split virus, quadrivalent, injectable, contains preservativeQuadrivalent code starting 2013/2014 season—
140Influenza, split virus, trivalent, PFInfluenza, split virus, trivalent, injectable, preservative freeTrivalent code reactivated for 2024/2025 season—
141Influenza, split virus, trivalent, preservativeInfluenza, split virus, trivalent, injectable, contains preservativeTrivalent code reactivated for 2024/2025 season—
10IPVpoliovirus vaccine, inactivatedIndia IAP, US CDC child
134Japanese Encephalitis IMJapanese Encephalitis vaccine for intramuscular administration—
163meningococcal B, OMVmeningococcal B vaccine, recombinant, OMV, adjuvantedNHS routine
162meningococcal B, recombinantmeningococcal B vaccine, fully recombinant—
203meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)meningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine 0.5mL dose, preservative freeNHS routine, Canada CIG, Australia NIP
136Meningococcal MCV4Omeningococcal oligosaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4O)Canada CIG
114meningococcal MCV4Pmeningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4P)Canada CIG
328Meningococcal oligosaccharide (MenACWY), (MenB), PFMeningococcal oligosaccharide conjugated (groups A, C, W, Y) and group B, 0.5 mL, preservative freeMeningococcal pentavalent vaccine strains ABCW and Y—
316Meningococcal polysaccharide (MenACWY-TT conjugate), (MenB), PFMeningococcal polysaccharide (groups A, C, Y, W) tetanus toxoid conjugate, meningococcal B recombinant vaccine, 0.5mL, preservative freeMeningococcal pentavalent vaccine strains ABCW and Y—
3MMRmeasles, mumps and rubella virus vaccineIndia IAP, US CDC child, US CDC adult, Canada CIG, Australia NIP
94MMRVmeasles, mumps, rubella, and varicella virus vaccineNHS routine, Canada CIG, Australia NIP
133Pneumococcal conjugate PCV 13pneumococcal conjugate vaccine, 13 valentNHS routine
215Pneumococcal conjugate PCV15, polysaccharide CRM197 conjugate, adjuvant, PFPneumococcal conjugate vaccine 15-valent (PCV15), polysaccharide CRM197 conjugate, adjuvant, preservative freeUS CDC adult, Canada CIG
216Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PFPneumococcal conjugate vaccine 20-valent (PCV20), polysaccharide CRM197 conjugate, adjuvant, preservative freeUS CDC adult, NHS routine, Canada CIG, Australia NIP
327Pneumococcal conjugate PCV21, polysaccharide CRM197 conjugate, PFPneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative freeUS CDC adult, Australia NIP
33pneumococcal polysaccharide PPV23pneumococcal polysaccharide vaccine, 23 valentNHS routine
175Rabies - IM Diploid cell cultureHuman Rabies vaccine from human diploid cell culture—
176Rabies - IM fibroblast cultureHuman rabies vaccine from Chicken fibroblast culture—
119rotavirus, monovalentrotavirus, live, monovalent vaccineNHS routine, Canada CIG, Australia NIP
116rotavirus, pentavalentrotavirus, live, pentavalent vaccineCanada CIG
305RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PFRespiratory syncytial virus (RSV), vaccine, bivalent, protein subunit RSV prefusion F, diluent reconstituted, 0.5 mL, preservative freeAdults 60 years and older, pregnant individualsUS CDC adult, NHS routine, Australia NIP
332RSV, mAb, clesrovimab-cfor, 0.7 mL, neonate and infant, PFRespiratory syncytial virus (RSV), monoclonal antibody, IgG1κ, (clesrovimab-cfor), 0.7 mL, neonate and infant, preservative freeRSV mAb for neonates and infants born during or entering first RSV season (Enflonsia)—
306RSV, mAb, nirsevimab-alip, 0.5 mL, neonate to 24 monthsRespiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 0.5 mL, neonates and children to 24 monthsRSV monoclonal antibody (Beyfortus)US CDC child
307RSV, mAb, nirsevimab-alip, 1 mL, neonate to 24 monthsRespiratory syncytial virus (RSV) monoclonal antibody, IgG1κ, (nirsevimab-alip), 1 mL, neonates and children to 24 monthsRSV monoclonal antibody (Beyfortus)US CDC child
326RSV, mRNA, injectable, PFRespiratory syncytial virus (RSV), mRNA, injectable, preservative freemRNA RSV vaccine added 2024—
303RSV, recombinant, protein subunit RSVpreF, adjuvant reconstituted, 0.5 mL, PFRespiratory syncytial virus (RSV), vaccine, recombinant, protein subunit RSV prefusion F, adjuvant reconstituted, 0.5 mL, preservative freeAdults 60 years and olderAustralia NIP
9Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)Canada CIG
113Td (adult), 5 Lf tetanus toxoid, preservative free, adsorbedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (5 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)Canada CIG
196Td, adsorbed, preservative free, adult use, Lf unspecifiedtetanus and diphtheria toxoids, adsorbed, preservative free, for adult use, Lf unspecifiedUsed when Td Lf specification is unknown—
115Tdaptetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbedIndia IAP, US CDC child, US CDC adult, NHS routine, Canada CIG, Australia NIP
223Tick-borne encephalitis, inactivated, PF, 0.25mLTick-borne encephalitis vaccine, inactivated, preservative free, 0.25mL dosePediatric dose vaccine—
224Tick-borne encephalitis, inactivated, PF, 0.5mLTick-borne encephalitis vaccine, inactivated, preservative free, 0.5mL doseAdult dose vaccine—
25typhoid, oraltyphoid vaccine, live, oral—
101typhoid, ViCPstyphoid Vi capsular polysaccharide vaccine—
75Vaccinia (smallpox, monkeypox), liveVaccinia (smallpox, monkeypox) vaccine, live—
206Vaccinia, smallpox monkeypox vaccine live, PF, SQ or ID injectionVaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injectionAssociated to FDA US Licensed product JYNNEOS, non-US tradenames IMVANEX, IMVAMUNE. Review CDC & FDA guidance for updates regarding administration—
21varicellavaricella virus vaccineIndia IAP, US CDC child, US CDC adult, Canada CIG
37yellow fever liveyellow fever vaccine liveThis is the YF vaccine that has been available in the US for years. It is stabilized with sorbitol and gelatin.—
183Yellow fever vaccine live - altYellow fever vaccine live - alternative formulation for vaccine shortageThis CVX is associated to an FDA unapproved drug to be used when there is a drug shortage. Stabilized with sorbitol and lactose and has been used outside the US for some time.—
187zoster recombinantzoster vaccine recombinantUS CDC adult, NHS routine, Canada CIG, Australia NIP
39 codes

Used outside the United States

CVXVaccineOn these schedules
173cholera, BivWC—
172cholera, WC-rBS—
516COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)SARS-COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
518COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)SARS-COV-2 COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
510COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (BIBP, Sinopharm)Pandemic Non-US Vaccine. Authorized by WHO - Counted toward immunity in US—
511COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (CoronaVac, Sinovac)Pandemic Non-US Vaccine. Authorized by WHO - Counted toward immunity in US—
502COVID-19 IV Non-US Vaccine (COVAXIN)SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN)Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion—
501COVID-19 IV Non-US Vaccine (QAZCOVID-IN)SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
503COVID-19 LAV Non-US Vaccine (COVIVAC)SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
519COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), ModernaSARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), ModernaPandemic Non-US Vaccine not Authorized by WHO - Is authorized by EU and counted toward immunity in US—
520COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTechSARS-COV-2 COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product (Comirnaty Bivalent), Pfizer-BioNTechPandemic Non-US Vaccine. Authorized by WHO 10/19/2022 - Counted toward immunity in US—
500COVID-19 Non-US Vaccine, UNSPECIFIEDSARS-COV-2 (COVID-19) Non-US Vaccine, UNSPECIFIEDUnspecified code to be used to record historic Non-US COVID-19 administration. May be used if the specific product or CVX code is not known.—
507COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharm + Inst of Micro, Chinese Acad of Sciences)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
509COVID-19 PS Non-US Vaccine (EpiVacCorona)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (EpiVacCorona)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
508COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Jiangsu Province Centers for Disease Control and Prevention)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
521COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSKSARS-COV-2 (COVID-19) vaccine SP, protein-based, adjuvanted, B.1.351 strain (VidPrevtyn Beta), Sanofi-GSKPandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
210COVID-19 vaccine, vector-nr, rS-ChAdOx1, PF, 0.5 mLSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-ChAdOx1, preservative free, 0.5 mLWHO authorized pandemic vaccine. Recognized towards immunity in US. AstraZeneca vaccine non-US WHO authorized tradenames/identifiers include VAXZEVRIA, AZD1222, ChAdOx1 nCoV-19, COVISHIELD—
506COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of BiotechnologySARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of BiotechnologyPandemic Non-US Vaccine. Authorized by WHO 5/19/2022 - Counted toward immunity in US—
504COVID-19 VVnr Non-US Vaccine (Sputnik Light)SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
505COVID-19 VVnr Non-US Vaccine (Sputnik V)SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
195DT, IPV adsorbedDiphtheria, Tetanus, Poliomyelitis adsorbedThis code should be used to document non-US vaccines for DT,IPV such as Revaxis—
170DTAP/IPV/HIB - non-USnon-US diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV)This CVX was split off from CVX 102, to correctly identify the contents of the vaccine.Canada CIG
198DTP-hepB-Hib Pentavalent Non-USDiphtheria, pertussis, tetanus, hepatitis B, Haemophilus Influenza Type b, (Pentavalent)This represents the non-US pentavalent vaccine. Should be used for historic documentation in USIndia UIP
102DTP-Hib-Hep BDTP- Haemophilus influenzae type b conjugate and hepatitis b vaccineThis CVX has been corrected. This non-US vaccine contained DTP, Hib and Hep B. It was withdrawn in 2007 .—
193Hep A-Hep B, pediatric/adolescenthepatitis A and hepatitis B vaccine, pediatric/adolescent (non-US)e.g. Twinrix Junior available in Canada—
169Hep A, live attenuatedHep A, live attenuated-IMThis vaccine is not available in the US.—
191meningococcal A polysaccharide (non-US)meningococcal A polysaccharide vaccine (non-US)—
192meningococcal AC polysaccharide (non-US)meningococcal AC polysaccharide vaccine (non-US)—
179OPV ,monovalent, unspecifiedNon-US monovalent oral polio vaccine, unspecified formulationThis is a non-US vaccine that may be seen in some immunization histories. It is composed of either Type 1, Type 2 or Type 3 oral polio vaccine.—
178OPV bivalentNon-US bivalent oral polio vaccine (types 1 and 3)This is a non-US vaccine that may be seen in some immunization histories.India UIP
177PCV10pneumococcal conjugate vaccine, 10 valentThis is a foreign vaccine—
324Poliovirus, inactivated, fractional-dose (fIPV)Non-US polio vaccine administered since 2016India UIP
514SARS-COV-2 COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D)SARS-COV-2 COVID-19 DNA Non-US Vaccine Product (Zydus Cadila, ZyCoV-D)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
513SARS-COV-2 COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Anhui Zhifei Longcom, Zifivax)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
517SARS-COV-2 COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Biological E Limited, Corbevax)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
515SARS-COV-2 COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901)SARS-COV-2 COVID-19 Protein Subunit Non-US Vaccine Product (Medigen, MVC-COV1901)Pandemic Non-US Vaccine not Authorized by WHO - not counted toward immunity in US—
512SARS-COV-2 COVID-19 VLP Non-US Vaccine (Medicago, Covifenz)SARS-COV-2 COVID-19 Virus Like Particle (VLP) Non-US Vaccine Product (Medicago, Covifenz)Pandemic Non-US Vaccine not Authorized by WHO - ACIP does recognize towards immunity in US—
77Tick-borne encephalitis vaccine (non-US)Non-US vaccine—
190Typhoid conjugate vaccine (TCV)Typhoid conjugate vaccine (non-US)India IAP
In MedAppz

Where vaccine codes are used

Each dose given in VaxVault carries its CVX code, and the schedules above are loaded so the next dose is due on the right day. In India, U-WIN Bridge gets the doses ready for the national U-WIN register.
Codes from the CDC’s CVX list (a US government work). Schedules:
  • India UIP: National Immunization Schedule (Universal Immunization Programme), Ministry of Health and Family Welfare, Government of India (National Health Mission).
  • India IAP: IAP-ACVIP Immunization Timetable 2023: Vaccines for Routine Use (0-18 years), Indian Academy of Pediatrics, Advisory Committee on Vaccines and Immunization Practices (ACVIP).
  • US CDC child: Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
  • US CDC adult: Recommended Adult Immunization Schedule for Ages 19 Years or Older, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
  • NHS routine: Complete routine immunisation schedule (UK), UK Health Security Agency.
  • Canada CIG: Canadian Immunization Guide: recommended immunization schedules (routine, previously immunized), Public Health Agency of Canada (National Advisory Committee on Immunization recommendations).
  • Australia NIP: National Immunisation Program Schedule (Australia), Australian Government Department of Health, Disability and Ageing.